NBRV - Nabriva Therapeutics EPS misses by $0.33 beats on revenue March, 11 2021 04:10 PM Nabriva Therapeutics plc Nabriva Therapeutics (NBRV): Q4 GAAP EPS of -$1.11 misses by $0.33.Revenue of $2.46M (+645.5% Y/Y) beats by $1.86M.Shares -1% AH.Press Release For further details see: Nabriva Therapeutics EPS misses by $0.33, beats on revenue